Neximmune announces $3.67 million registered direct offering priced at-the-market under nasdaq rules

Gaithersburg, md., feb. 02, 2024 (globe newswire) -- neximmune, inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under nasdaq rules.
NEXI Ratings Summary
NEXI Quant Ranking